{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"124","value":"367"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)","title":"Maximum Plasma Concentration (Cmax) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"micrograms/millilitres (μg/ml)"}